News

bit.bio and Charles River Laboratories discuss the potential of precision reprogrammed human cells.

The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine. 

Leading experts across academia and industry share their thoughts into the challenges of in vitro cell models.

The article offers 6 tips for successful pharma startups.

This case study delves into the company story, technology and vision.

Read the TechRound feature on Cambridge University spin-outs, including bit.bio. Learn about the origins of our opti-ox™ technolog...

Technology Networks cover the development, benefits and applications of ioSkeletal Myocytes.

Founder and CEO Dr Mark Kotter joined the experts who have given their thoughts on what is to come for the health sector in 2022.